Showing 4951-4960 of 9244 results for "".
Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicBuild Leadership Skills in Staff Members
https://practicaldermatology.com/topics/practice-management/build-leadership-skills-in-staff-members/19110/Todd E. Schlesinger, MD discusses strategies for cultivating leadership among staff and highlights the importance of positioning staff to succeed.Dr. Matthias Donelan
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/scaarfx-donelan-/19250/Dr. Donelan has been treating patients with scarring following burns for more than 35 years. Although great progress has been made, he found it difficult to bring patients back to their pre-injury state. Learn about his experience with the Lumenis UltraPulse and how it has impacted patients' qualityThe Evolving Needs of the Modern Patient
https://practicaldermatology.com/videos/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.Noah Worcester 2024: Dr. Mesinkovska on Alopecia Areata
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-mesinkovska-alopecia-areata/24586/Natasha Atanaskova Mesinkovska. MD, PhD, summarizes her lecture on JAK inhibitors and minoxidil at the 2024 Noah Worcester Dermatological Society meeting.Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/videos/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.Unplugged: Cutting-Edge Aesthetic Medicine
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/unplugged-cutting-edge-aesthetic-medicine/20142/Jeanine Downie, MD shares pearls from her presentation in the Unplugged session she co-chaired with José Montes, MD. She discusses some of the latest tightening devices for the face, neck, and body, including EmFace, Zaffiro, and Sofwave. Plus, she reviews topics presented by colleagues throughout tManaging Patients with Atypical Nevi and Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/managing-patients-with-atypical-nevi-and-melanoma/19982/Monitoring patients with several atypical nevi who are at high risk for melanoma is very challenging. Steven Q. Wang, MD offers tips for improving diagnostic accuracy and discusses the role of dermoscopy in detecting melanoma as well as non-melanoma skin cancers at much earlier rates.DermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weighPatients types that may be a great fit for ILUMYA™
https://practicaldermatology.com/topics/psoriasis/patients-types-that-may-be-a-great-fit-for-ilumya/19859/See how ILUMYA™ is a treatment option for a diverse range of patients with moderate-to-severe plaque psoriasis, including bio-naive and bio-experienced patients, and those aged 65 years or older.